Infant Formula Milk Powder

Why Infant Formula Demands Specialist Expertise

Infant formula sits at the intersection of food manufacturing, pharmaceutical-grade quality control and consumer-brand reputation management. The barriers to entry are high because the consequences of getting it wrong are severe — both for the infants who consume the product and for the businesses that manufacture it.

A single contamination event can result in fatalities, multi-billion-pound brand damage, regulatory shutdown, criminal prosecution of directors, and category-wide loss of consumer trust. The 2008 Chinese melamine adulteration crisis, the 2022 Abbott Cronobacter recall and the 2013 Fonterra botulism scare are each instructive in different ways — each one showed how decisions taken months or years earlier in formulation, supply chain design or quality system design determined whether the response was a managed recall or a brand-threatening crisis.

The technical and commercial questions in infant formula manufacturing are not edge cases. They are the centre of the business: which processing route, what level of microbiological control, which suppliers, what redundancy, what testing regime, how to balance cost against risk. Independent technical input on these decisions is valuable precisely because the consequences are not abstract.

What We Cover

Processing Routes — The Critical Choice

The choice of processing route is the most important technical decision in an infant formula project. It determines microbiological risk, ingredient flexibility, capex, operating cost and ultimately the commercial positioning the product can support. There are three principal routes.

Wet-mix (integral) processing

All ingredients are reconstituted into a liquid stream, heat-treated, evaporated, and spray-dried as a single integrated process. This is the most microbiologically secure route because every ingredient passes through validated heat treatment. It is the standard for high-volume major brand manufacturing.

The limitations are real. Ingredients that are damaged by heat — vitamins, probiotics, some functional lipids — cannot easily be added at the wet-mix stage. Capex is high because the process integrates evaporator, dryer, and pre-treatment in one continuous line. Changeover between recipes takes time and creates rinse losses. The route suits standardised, high-volume products.

Dry-blend processing

A base powder — typically containing the heat-stable bulk of the formulation — is manufactured by wet-mix or sourced as an ingredient. Vitamins, minerals, premixes and any heat-sensitive functional ingredients are then blended into the base powder in a dedicated high-care dry-blending area.

This gives flexibility — multiple SKUs can be produced from common base powders with different premix additions, and heat-sensitive ingredients can be included without thermal damage. The microbiological risk is higher because the dry-added ingredients are not subsequently heat-treated. Strict supplier control, environmental monitoring and product testing are essential. Many premium and specialist brands use dry-blend because of the flexibility it provides.

UHT ready-to-feed (liquid)

The formula is prepared as a liquid, UHT-sterilised and aseptically packaged into cartons or bottles. The microbiological risk is the lowest of the three routes because the final product is commercially sterile. Reconstitution error by the carer is also eliminated.

Capex and operating cost are higher than powder, the product is bulkier and more expensive to ship, and shelf life is shorter (typically 6 to 12 months). Ready-to-feed dominates the medical nutrition segment (premature infants, infants with specific medical needs) and is growing in premium consumer segments for convenience and safety positioning.

Raw Materials & Formulation

Protein

Infant formula protein is normally a blend of skimmed milk powder and whey-based ingredients adjusted to give a casein-to-whey ratio that approximates human milk (typically 40:60 in stage 1 formulas, shifting towards higher casein in follow-on stages). Demineralised whey powders — Demi 50, Demi 70, Demi 90 indicating the percentage of minerals removed — are used because standard whey carries too high a mineral load. The cost of demineralised whey increases sharply with the demineralisation level, so formulators normally select the lowest level that meets the mineral specification.

Alternative protein sources are growing. Goats' milk is approved in the EU (since 2012), Canada and the US. Sheep's milk is approved in China. Camel milk infant formula is manufactured in the UAE and elsewhere. Plant protein-based infant formulas remain limited and contested — soy formula has a long history but ongoing safety questions around phytoestrogens. Vegan infant formula development is active but faces both regulatory and clinical hurdles.

Fat

The fat blend is normally a mixture of vegetable oils selected to give the target fatty acid profile. Palm or palm olein (for palmitic acid), high-oleic sunflower or rapeseed (for oleic acid), and soy or sunflower (for linoleic acid) are common base oils. Single-cell oils provide DHA (algal) and ARA (fungal). Structured lipids, including positionally engineered triglycerides that approximate the structure of human milk fat, are used in some premium products.

Oil oxidation is a critical control point. Vegetable oils introduce both the most expensive functional risk and the most demanding traceability requirement. Single-source dependency, supplier audit, antioxidant strategy and oxidative stability testing all need careful design.

Carbohydrate

Lactose is the dominant carbohydrate, normally sourced as a high-purity pharmaceutical or food-grade ingredient. Prebiotics — galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) — are commonly included to support gut microbiome development. Human milk oligosaccharides (HMOs), particularly 2'-fucosyllactose, are now produced by fermentation and included in premium products.

Vitamins, minerals and premix

The vitamin and mineral premix is normally a single ingredient supplied by a specialist premix manufacturer (DSM-Firmenich, Glanbia Nutritionals, Watson Inc and others). Premix specification is detailed: nutrient overage (typically 10 to 30% to compensate for processing losses and shelf-life decay), particle size, flowability, segregation behaviour, microbiological standard, allergen status, and country-specific composition for multi-market products.

Regulatory Frameworks

Infant formula is one of the most heavily regulated food categories worldwide. Multi-market products must comply with the most restrictive applicable standard, which adds significant complexity to formulation and product development.

The principal frameworks

• Codex Alimentarius Standard 72-1981 — the international reference standard, used as the basis for many national rules
• EU Regulation 2016/127 and supporting delegated acts — comprehensive composition, labelling and marketing rules applicable in the EU and (with adjustments) the UK
• WHO and FAO guidance — including the International Code of Marketing of Breast-milk Substitutes (the WHO Code), which constrains how infant formula can be marketed
• US FDA — the Infant Formula Act and 21 CFR 106-107, with strict pre-market notification requirements
• China GB standards and SAMR registration — one of the most demanding regulatory environments globally, requiring extensive on-site inspection and registration
• National regulations — significant variation in the GCC, India, the Russian Federation, Mexico and elsewhere

The composition trade-off

Each market sets its own upper and lower limits for protein, fat, carbohydrate, individual vitamins and minerals, and contaminants. When formulating for multiple markets, the practical approach is to identify the most restrictive limit on each parameter and set the product specification within that. If three target markets allow iron between 0.45 and 1.2 mg/100 kcal, 0.5 and 1.5 mg/100 kcal, and 0.6 and 1.3 mg/100 kcal respectively, the formulation has to sit between 0.6 and 1.2 mg/100 kcal to be compliant in all three. After allowing for normal manufacturing tolerance, the operating range becomes narrow.

Microbiological Control and Quality Systems

The defining quality challenge in powdered infant formula is microbiological. The product cannot be heat-treated effectively by the consumer at the point of preparation. Cronobacter sakazakii and Salmonella have both caused fatalities in infants from contaminated powder, and the standard environmental controls applied elsewhere in food manufacturing are not sufficient.

High-care zoning

Modern infant formula plants are designed around high-care and high-risk area concepts adapted from pharmaceutical practice. The dry-blending area in particular is treated as a critical control zone — air pressure cascades, personnel changing protocols, dedicated equipment, validated cleaning regimes, and intensive environmental monitoring all apply. Cross-contamination from areas of higher microbiological risk into the high-care zone is the single most important control to design out.

Environmental monitoring

A robust environmental monitoring programme is non-negotiable. Sampling regimes typically cover all surfaces in the high-care area at defined frequencies, with escalating responses to any positive findings. Cronobacter sampling is particularly demanding because the organism is hardy, hard to detect at low levels, and grows readily in dry-powder environments. Many leading manufacturers run dedicated Cronobacter monitoring programmes with detection levels significantly more sensitive than regulatory minimums.

Supplier control

For dry-blended ingredients in particular, the supplier is part of the manufacturing process. Premix manufacturers, demineralised whey suppliers, and ingredient blenders all need to operate to standards equivalent to the final manufacturer. Supplier audit, qualification, ongoing monitoring and contractual commitments to quality standards are core to the operation.

Out-of-Specification Product and Disposal

Every infant formula manufacturer will produce some out-of-specification product — from process upsets, packaging defects, composition deviations, or end-of-shelf-life inventory. The handling of this product is a significant due diligence point.

Standard routes are reprocessing into animal feed ingredients (subject to local regulation), use in confectionery or bakery (only if the deviation is composition rather than safety related, and the product is otherwise compliant with food law), or destruction. The traceability documentation must be sufficient to demonstrate that no out-of-specification infant formula has entered the human infant food chain. Some of the most damaging incidents in the sector have involved product that was intended for animal feed or destruction finding its way back to human consumption.

Frequently Asked Questions

What are the main processing routes for infant formula milk powder?

Three principal routes are used commercially: wet-mix (integral) processing, where all ingredients are reconstituted, heat-treated and spray-dried as a single integrated process; dry-blend processing, where a base powder is blended with vitamins, minerals and other heat-sensitive ingredients after spray drying; and UHT ready-to-feed liquid, where the formula is sterilised and aseptically packaged in cartons or bottles. Wet-mix gives the highest microbiological security but limits which ingredients can be added. Dry-blend allows heat-sensitive ingredients but carries higher microbiological risk because the dry-added ingredients are not subsequently heat-treated. UHT ready-to-feed is the most secure option for vulnerable infants but the most expensive to produce.

What regulations apply to infant formula?

The principal frameworks are Codex Alimentarius Standard 72-1981 (the international reference), WHO and FAO guidance, EU Regulation 2016/127 (and the supporting delegated acts) for the EU and UK, and the relevant national legislation in each destination market. Many countries also operate their own composition limits, labelling requirements, contaminant standards and registration regimes — China (GB standards and SAMR registration), the US (FDA infant formula rules), the GCC, and others. Product intended for multiple markets must be formulated to comply with the most restrictive applicable standard.

What are the main raw materials in infant formula?

Protein sources include skimmed milk powder, whey protein concentrates and demineralised whey powders (typically Demi 50, 70, 90 — the number indicating the percentage of minerals removed). Fat sources are usually vegetable oil blends formulated to match the target fatty acid profile, with sometimes the addition of structured lipids or single-cell oils for LCPUFAs (DHA, ARA). Carbohydrate is normally lactose, with optional addition of prebiotics (GOS, FOS). Vitamins and minerals are added as a premix. Some products also include probiotics, nucleotides, MFGM ingredients, and human milk oligosaccharides (HMOs).

Why is microbiological control so critical for infant formula?

Infants — particularly newborns and premature infants — are highly vulnerable to bacterial infections. Cronobacter sakazakii and Salmonella in powdered formula have caused fatalities. The product cannot be heat-treated by the consumer effectively (preparation temperatures recommended by WHO are 70 degrees C, but real-world practice varies). Manufacturing controls therefore have to deliver a product safe at preparation, which means tight raw material specifications, controlled environment dry-blending, validated cleaning and segregation, robust environmental monitoring and rapid response to any positive findings.

What does an infant formula factory cost to build?

Capex varies widely with capacity, technology and geography. A small dry-blend plant suitable for a niche brand can be built for around £10 to 20 million. A medium wet-mix integral plant including evaporator, spray dryer, dry-blending and packaging is typically £50 to 150 million. Large modern integrated plants with multiple stages, high-care areas, and full automation can exceed £250 million. Operating costs are dominated by milk, whey, vegetable oils and the premix, with energy and labour also material. We provide capex and opex benchmarking for greenfield and expansion projects.

What happens to out-of-specification infant formula powder?

Out-of-specification or downgraded powder cannot be sold for human infant consumption. Standard disposal routes include reprocessing into animal feed ingredients (where regulations permit), use in confectionery or bakery (if the deviation is composition rather than safety related and the product is otherwise compliant), or destruction. Traceability documentation must show end-to-end disposal so the manufacturer can demonstrate due diligence and protect brand reputation — the risk of downgraded product entering human food channels is one of the most serious reputational exposures in the sector.

Further reading: John Watson publishes articles on dairy industry topics on LinkedIn — from infant formula safety and milk supply to plant design, yield improvement and dairy commodity outlook. Browse all articles by John Watson on LinkedIn →

See our related corporate responsibility & ethics, due diligence, expert witness, spray drying, membrane filtration, UHT and factory design pages, or browse all consultancy services.